SLNO - Soleno Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0300
+0.0300 (+1.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0000
Open1.9900
Bid0.0000 x 1100
Ask2.7500 x 2900
Day's Range1.9900 - 2.0632
52 Week Range1.1100 - 5.0700
Volume43,706
Avg. Volume1,569,272
Market Cap64.463M
Beta (3Y Monthly)-0.41
PE Ratio (TTM)N/A
EPS (TTM)-0.6360
Earnings DateMay 14, 2019 - May 20, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • GlobeNewswire22 days ago

    Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

    REDWOOD CITY, Calif., April 03, 2019 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • Will Capnia Continue to Surge Higher?
    Zacks29 days ago

    Will Capnia Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Capnia.

  • Are You Looking for a Top Momentum Pick? Why Capnia, Inc. (SLNO) is a Great Choice
    Zackslast month

    Are You Looking for a Top Momentum Pick? Why Capnia, Inc. (SLNO) is a Great Choice

    Does Capnia, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • GlobeNewswirelast month

    Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference

    REDWOOD CITY, Calif., March 25, 2019 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • GuruFocus.comlast month

    Soleno Therapeutics Inc (SLNO) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Soleno Therapeutics Inc (NASDAQ:SLNO) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • ACCESSWIRElast month

    Soleno Therapeutics, Analyst Review and Pipeline Progress

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies isissuing a comprehensive ...

  • GlobeNewswirelast month

    Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

    REDWOOD CITY, Calif., March 18, 2019 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • ACCESSWIRElast month

    Four Healthcare Stocks Picking Up Speed On Friday

    CORAL GABLES, FL / ACCESSWIRE / March 15, 2019 / The future successes of the healthcare stock market are intrinsically entwined with whether, or not, healthcare companies are aptly prepared to rise to ...

  • Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today
    InvestorPlacelast month

    Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today

    Soleno Therapeutics (NASDAQ:SLNO) had a Friday to remember as the biopharmaceutical company made some headway in a successful clinical trial of a treatment for a genetic disorder.Source: FlickrThe Redwood City, Calif.-based business announced that its Phase 3 trial of a tablet designed for patients afflicted with Prader-Willi syndrome (PWS) showed some improvement. The Data Safety Monitoring Board (DSMB) is recommending that the trial, which is operating under the moniker DESTINY PWS, for a diazoxide choline controlled-release tablet move forward as is.Soleno Therapeutics is helping to ameliorate PWS patients, which is an illness that is mostly known for the symptom hyperphagia. This symptom makes those with the condition feel like they are always hungry. PWS can also lead patients to experience behavioral issues, including cognitive disabilities, lower-than-average muscle tone, an excess in body fat and incomplete sexual development.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are delighted with the DSMB's positive recommendation to continue the Phase 3 trial as planned as it further supports DCCR's safety profile," Dr. Anish Bhatnagar, Soleno CEO , said in a statement. "We are continuing to enroll patients with 14 sites activated in DESTINY PWS."Dr. Bhatnagar also announced that patients will continue their treatment into C602, which is a nine-month study for patients who are a part of DESTINY PWS.SLNO stock is skyrocketing about 213% on Friday following the news, which has the potential to improve the quality of hundreds of thousands of people. Roughly one in every 12,000 to 15,000 people is afflicted with PWS More From InvestorPlace * 15 Stocks Sitting on Huge Piles of Cash * 5 Airline Stocks In Serious Trouble * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% Compare Brokers The post Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today appeared first on InvestorPlace.

  • Benzingalast month

    The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...

  • Business Wirelast month

    Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has recommended the continuation of the Company’s Phase III trial in Prader-Willi Syndrome (PWS) patients, DESTINY PWS, without any changes. “We are delighted with the DSMB’s positive recommendation to continue the Phase III trial as planned as it further supports DCCR’s safety profile,” said Dr. Anish Bhatnagar, Chief Executive Officer of Soleno.

  • GlobeNewswirelast month

    Soleno Therapeutics to Participate in Two Upcoming Investor Conferences

    REDWOOD CITY, Calif., March 11, 2019 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • GlobeNewswire4 months ago

    Soleno Therapeutics Announces $16.5 Million Private Placement

    Financing Led by Abingworth; Andrew Sinclair, Partner, to Join Soleno’s Board Funding to Support Ongoing Phase III Clinical Program (DESTINY PWS) for DCCR in Prader-Willi.

  • Simply Wall St.4 months ago

    Is Soleno Therapeutics, Inc.’s (NASDAQ:SLNO) CEO Pay Justified?

    In 2014 Anish Bhatnagar was appointed CEO of Soleno Therapeutics, Inc. (NASDAQ:SLNO). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...

  • GlobeNewswire5 months ago

    Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that clinical data from a Phase II study (PC025) of diazoxide choline controlled release (DCCR) investigating the effects of DCCR treatment on hyperphagia and fat loss in patients with Prader-Willi Syndrome (PWS) were delivered today in a poster presentation at the Obesity Society Meeting 2018, taking place this week in Nashville, TN. “While the hallmark characteristic of PWS is hyperphagia, PWS patients also experience ectopic accumulation of body fat, obesity and associated cardiometabolic complications, which is the leading cause of death of PWS patients,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno.

  • GlobeNewswire5 months ago

    Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results

    REDWOOD CITY, Calif., Nov. 15, 2018 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.